@commonsenseplay Sarepta already monetized a big portion of the asset upfront in 2019 when they signed the licensing agreement. Roche owns ex-U.S. commercialization and books those revenues. Sarepta reviews a small amount royalties, but the majority of international upside sits with Roche.